English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

In this study, zinc-62 was prepared at radiopharmaceutical grade (for  62 Zn/ 62 Cu generator production) using  nat Cu( p ,  xn ) reaction with the production yield of 5.9 mCi/ μ Ah at 30 MeV proton energy (radiochemical separation yield &gt;95%, radionuclidic purity &gt;99% and radiochemical purity &gt;99%). In the next step, rituximab was successively labeled with [ 62 Zn]-ZnCl 2  after conjugation with p-SCN-Bz-DOTA followed by molecular filtration and determination of the average number of DOTA conjugated per mAb (6:1) by spectrophotometric method. Radiochemical purity (&gt;97%, measured by ITLC and HPLC), integrity of protein after radiolabeling (gel electrophoresis) and stability of [ 62 Zn]-DOTA-rituximab (in final formulation, and human serum) were determined 1–8 h as well as biodistribution studies in wild-type rats followed by coincidence imaging for 6 h. However, the accumulation of the radiolabeled antibody was not consistent with the former reported rituximab conjugates. [ 62 Zn]-labeled monoclonal antibodies and fragments can be prepared as potential  in vivo  PET generators for molecular imaging however, the search for application of stable zinc complexes must be continued.

Development of [ 62 Zn/ 62 Cu]-DOTA-rituximab as a possible novel in vivo PET generator for anti-CD20 antigen imaging